Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

20%

1 trials in Phase 3/4

Results Transparency

0 of 2 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

N/A

2(50.0%)

Phase 3

1(25.0%)

Phase 2

1(25.0%)

4Total

N/A(2)

Phase 3(1)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials

NCT07500116Not ApplicableRecruiting

NORA-HOME: An Ambulatory Multimodal Monitoring Model In Patients With Minor Stroke And Transient Ischemic Attacks

Role: collaborator

NCT06078384Phase 2Recruiting

Pembrolizumab and Chemotherapy Treatment or no Treatment Guided by the Level of TILs in Resected Early-stage TNBC

Role: collaborator

NCT06522633Phase 3Completed

Esophageal Dysfunction Associated With Opioids: Clinical Response and Manometric Findings After Opioid Discontinuation

Role: collaborator

NCT06611046Completed

MicroRNA Profile As a Biomarker of Liver Damage in Different Types of Liver Donors.

Role: collaborator

NCT05148728Not ApplicableUnknown

Active Surveillance vs in Office Fulguration for Low Grade Bladder Cancer Tumors

Role: lead

All 5 trials loaded